# Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Source: https://onco.cc/trials/nct06228053/  
OnCo record `nct06228053` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Enzalutamide in prostate cancer, run by Syntrix Biosystems, Inc., now recruiting.

## Summary

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer is a phase 2 interventional study registered as NCT06228053 by Syntrix Biosystems, Inc., with 53 participants planned, started 2024-11-18 and due to reach its primary completion in 2027-06-30. Interventions recorded: SX-682, Enzalutamide. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06228053
- Phase: 2
- Setting: A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial
- Sponsor: Syntrix Biosystems, Inc.
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT06228053: https://clinicaltrials.gov/study/NCT06228053

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/)

---
JSON: https://onco.cc/api/v1/entities/nct06228053.json